CorMedix to Raise $2,M in Offering

CorMedix (NYSE MKT: CRMD) today announced that it has entered into securities purchase agreements with investors pursuant to which it has agreed to sell 200,000 shares of Series C-3 Non-Voting Convertible preferred stock and a warrant to purchase up to 1,000,000 shares of common stock for aggregate gross proceeds of $2,000,000.  This is the second tranche of funds contemplated and priced in the company's October 2013 Series C preferred stock financing to bolster the Company's cash position which management now projects to be sufficient to fund operations through the achievement of a break even sales run rate.  The net proceeds of the financing will be used for general corporate purposes, including the development and commercialization of Neutrolin®, and working capital and capital expenditures.  No underwriter or placement agent was used in this transaction.  See full press release